Floatz logo

Enzalutamide

Prostate Carcinoma

PfizerSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

107 Active assets in the Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Leuporelin
Mayo Clinic
Phase 4BBB
Prednisone
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone
Mayo Clinic
Phase 4BBB
Docetaxel
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 49 →

Same molecule, other indications

Enzalutamide is also rated in:

castration-resistant prostate carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
breast carcinomaActive
BB
Indicative · Phase 2
68 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →